Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Int Immunopharmacol ; 98: 107904, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34214886

ABSTRACT

Dysregulation of phosphoinositide 3-kinase δ (PI3Kδ) signaling pathway has been implicated in the pathogenesis of inflammatory and autoimmune diseases. Parsaclisib (INCB050465) represents a potent and selective PI3Kδ inhibitor, which is being clinically investigated for treatment of autoimmune hemolytic anemia and hematological malignancies. We characterized the potential of parsaclisib to ameliorate autoimmune mechanisms implicated in the pathophysiology of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). Spontaneous mouse models of SLE and SS were utilized to elucidate the efficacy of orally administered parsaclisib on autoreactive B-cell-mediated antibody-driven disease. Parsaclisib significantly reduced disease symptoms and pathology in three distinct mouse models of SLE. Parsaclisib effectively preserved renal function as measured by glomerular filtration rate, abrogated histopathological evidence of nephritis, modulated discrete immune cell subsets, and decreased anti-dsDNA antibody level. Furthermore, parsaclisib demonstrated efficacy in two spontaneous mouse models of SS. Oral parsaclisib treatment ameliorated the severity of salivary gland inflammation and reduced circulating levels of autoantibodies. Parsaclisib mediated improvement of salivary gland inflammation coincided with reduced B-cell activating cytokine (BAFF) in saliva. Transcriptomic analysis of kidney and salivary gland tissues revealed a downregulation in inflammatory gene expression consistent with PI3Kδ pathway inhibition. Parsaclisib reduced autoreactive B-cells and autoantibody levels, and significantly improved nephritis and salivary gland inflammation. These data provide the scientific rationale for PI3Kδ inhibition as a therapeutic strategy for treatment of B-cell-mediated antibody-driven autoimmune diseases.


Subject(s)
Autoantibodies/blood , Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors , Lupus Erythematosus, Systemic/drug therapy , Pyrazoles/pharmacology , Pyrimidines/pharmacology , Pyrrolidines/pharmacology , Sjogren's Syndrome/drug therapy , Animals , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Class I Phosphatidylinositol 3-Kinases/metabolism , Disease Models, Animal , Humans , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/immunology , Mice , Pyrazoles/therapeutic use , Pyrimidines/therapeutic use , Pyrrolidines/therapeutic use , Sjogren's Syndrome/blood , Sjogren's Syndrome/immunology
2.
Front Pharmacol ; 12: 650295, 2021.
Article in English | MEDLINE | ID: mdl-33981229

ABSTRACT

Hyperinflammatory syndromes comprise a heterogeneous group of disorders characterized by severe inflammation, multiple organ dysfunction, and potentially death. In response to antigenic stimulus (e.g., SARS-CoV-2 infection), overactivated CD8+ T-cells and macrophages produce high levels of proinflammatory cytokines, such as IFN-γ, TNF-α, IL-6, and IL-12. Multiple inflammatory mediators implicated in hyperinflammatory syndromes utilize the Janus kinase-signal transducers and activators of transcription (JAK-STAT) cascade to propagate their biological function. Our findings demonstrate that oral ruxolitinib dosing designed to mimic clinically relevant JAK-STAT pathway inhibition significantly reduces the harmful consequences of immune overactivation in multiple hyperinflammatory models. In contrast to monoclonal antibody therapies targeting a single cytokine, ruxolitinib effectively downregulates the functional effect of multiple cytokines implicated in hyperinflammatory states, without broad immunosuppression.

3.
Eur J Pharmacol ; 885: 173505, 2020 Oct 15.
Article in English | MEDLINE | ID: mdl-32861662

ABSTRACT

Pharmacological modulation of the Janus kinase (JAK) family has achieved clinically meaningful therapeutic outcomes for the treatment of inflammatory and hematopoietic diseases. Several JAK1 selective compounds are being investigated clinically to determine their anti-inflammatory potential. We used recombinant enzymes and primary human lymphocytes to assess the JAK1 specificity of itacitinib (INCB039110) and study inhibition of signal transducers and activators of transcription (STAT) signaling. Rodent models of arthritis and inflammatory bowel disease were subsequently explored to elucidate the efficacy of orally administered itacitinib on inflammatory pathogenesis. Itacitinib is a potent and selective JAK1 inhibitor when profiled against the other JAK family members. Upon oral administration in rodents, itacitinib achieved dose-dependent pharmacokinetic exposures that highly correlated with STAT3 pharmacodynamic pathway inhibition. Itacitinib ameliorated symptoms and pathology of established experimentally-induced arthritis in a dose-dependent manner. Furthermore, itacitinib effectively delayed disease onset, reduced symptom severity, and accelerated recovery in three distinct mouse models of inflammatory bowel disease. Low dose itacitinib administered via cannula directly into the colon was highly efficacious in TNBS-induced colitis but with minimal systemic drug exposure, suggesting localized JAK1 inhibition is sufficient for disease amelioration. Itacitinib treatment in an acute graft-versus-host disease (GvHD) model rapidly reduced inflammatory markers within lymphocytes and target tissue, resulting in a marked improvement in disease symptoms. This is the first manuscript describing itacitinib as a potent and selective JAK1 inhibitor with anti-inflammatory activity across multiple preclinical disease models. These data support the scientific rationale for ongoing clinical trials studying itacitinib in select GvHD patient populations.


Subject(s)
Azetidines/pharmacology , Inflammation/drug therapy , Isonicotinic Acids/pharmacology , Janus Kinase 1/antagonists & inhibitors , Animals , Arthritis, Experimental/drug therapy , Azetidines/pharmacokinetics , Azetidines/therapeutic use , Chemokine CCL2/drug effects , Colitis/chemically induced , Colitis/drug therapy , Dose-Response Relationship, Drug , Graft vs Host Disease/drug therapy , Humans , Inflammatory Bowel Diseases/drug therapy , Isonicotinic Acids/pharmacokinetics , Isonicotinic Acids/therapeutic use , Lymphocytes/drug effects , Mice , Mice, Inbred BALB C , Primary Cell Culture , Rats , Rats, Inbred Lew , STAT Transcription Factors/drug effects , STAT3 Transcription Factor/drug effects , Signal Transduction/drug effects , T-Lymphocytes/drug effects
4.
Front Immunol ; 11: 620098, 2020.
Article in English | MEDLINE | ID: mdl-33658996

ABSTRACT

The goal of this study was to elucidate the anti-pruritic and anti-inflammatory efficacy of ruxolitinib cream in experimentally-induced dermatitis. Atopic dermatitis (AD), the most common chronic relapsing inflammatory skin disease, significantly impairs patients' quality of life, with pruritus being a common complaint. The sensation of itch results from the interplay between epidermal barrier dysfunction, upregulated immune signaling and the activation of the central nervous system. The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway plays a central role in pro-inflammatory cytokine signaling in AD. Ruxolitinib cream is a potent and selective JAK1/2 inhibitor currently undergoing clinical evaluation in adults with mild-to-moderate AD (NCT03745638, NCT03920852 and NCT03745651). The efficacy of ruxolitinib cream was tested in murine models of acute and chronic dermatitis and was also characterized in an ex vivo human skin dermatitis model. Ruxolitinib cream was highly effective at ameliorating disease symptoms in multiple murine dermatitis models through downregulation of T helper (Th)2-driven inflammation, resulting in reduced skin thickening and decreased itch. Pathway analysis of mouse ear tissue and human skin explants underscored the role for ruxolitinib in ameliorating inflammation and reducing itch via modulation of the JAK-STAT pathway. Together, the data offer a strong rationale for the use of ruxolitinib cream as a potent therapeutic agent for the clinical management of atopic dermatitis.


Subject(s)
Dermatitis/drug therapy , Janus Kinase Inhibitors/therapeutic use , Pruritus/drug therapy , Pyrazoles/therapeutic use , Administration, Cutaneous , Animals , Betamethasone/administration & dosage , Betamethasone/therapeutic use , Clobetasol/administration & dosage , Clobetasol/therapeutic use , Cytokines/biosynthesis , Cytokines/genetics , Cytokines/toxicity , Disease Models, Animal , Drug Eruptions/drug therapy , Drug Eruptions/immunology , Drug Evaluation, Preclinical , Female , Fluorescein-5-isothiocyanate/toxicity , Grooming/drug effects , Humans , In Vitro Techniques , Interleukin-33/genetics , Janus Kinase Inhibitors/administration & dosage , Lymphocyte Subsets/drug effects , Lymphocyte Subsets/immunology , Mice , Mice, Inbred BALB C , Mice, Transgenic , Nitriles , Ointments , Organ Culture Techniques , Pyrazoles/administration & dosage , Pyrimidines , Random Allocation , Signal Transduction/drug effects , Skin/drug effects , Specific Pathogen-Free Organisms , T-Lymphocytes, Helper-Inducer/drug effects , T-Lymphocytes, Helper-Inducer/immunology , Transcriptome , Thymic Stromal Lymphopoietin
5.
Curr Protoc Pharmacol ; 86(1): e65, 2019 09.
Article in English | MEDLINE | ID: mdl-31539922

ABSTRACT

The non-obese diabetic (NOD) mouse model is the most widely described and validated method for investigating human primary Sjögren's syndrome (SS) and represents a useful model for translational studies. However, the systemic disease manifestation in NOD mice is sensitive to the housing environment, as stress modulates the immune system, so it is essential to confirm that readouts are robust, reproducible, and sensitive to known clinical treatments. This protocol describes the establishment of the spontaneous NOD model of SS and underscores the necessity of model validation to ensure that the housing environment is compatible. © 2019 by John Wiley & Sons, Inc.


Subject(s)
Disease Models, Animal , Sjogren's Syndrome , Animals , Female , Mice, Inbred NOD , Salivation
6.
Front Immunol ; 9: 2231, 2018.
Article in English | MEDLINE | ID: mdl-30364107

ABSTRACT

IgE is the key mediator of allergic responses. Omalizumab, an IgE-specific monoclonal antibody that depletes IgE, is effective for treating severe allergic asthma. The need for frequent administration of the expensive drug, however, limits its applications. Taking advantage of T cell memory, adoptive T cell therapy (ACT) targeting IgE-producing cells has the potential to achieve long-term suppression of IgE and relief of symptoms for severe allergic diseases. The transmembrane form of IgE (mIgE), which is present on all IgE-producing cells, serves as an excellent molecular target for ACT that employs chimeric antigen receptors (CARs). Here, we designed and tested CARs that use the extracellular domain of high affinity IgE receptor, FcεRIα, for mIgE recognition. When expressed on Jurkat T cells, FcεRIα-based CARs mediated robust responses in terms of CD69 upregulation to U266 myeloma cells expressing low levels of mIgE. FcεRIα-based CARs specifically recognized cells expressing mIgE, but not cells with secreted IgE captured through Fcε receptors. CAR+ Jurkat cells did not respond to LAD2 mast cells with secreted IgE bound through FcεRI or Ramos cells with secreted IgE bound through FcεRII. Co-culture of CAR+ Jurkat cells and LAD2 mast cells with IgE bound did not trigger LAD2 cell degranulation. The activity of CAR using wild type FcεRIα for mIgE binding was inhibited by the presence secreted IgE, which likely blocked CAR-mIgE interaction. The activities of CARs using low affinity mutants of FcεRIα, however, tolerated secreted IgE at relatively high concentrations. Moreover, primary human CD8+ T cells expressing a low affinity mutant CAR responded to U266 cells with INFγ production and cytotoxicity despite the presence of secreted IgE. The potency, specificity, and robustness of our CAR design, combined with repaid advances in the safety of ACT, hold promise for novel and highly effective cell-based therapies against severe allergic diseases.


Subject(s)
Immunoglobulin E/immunology , Receptors, Chimeric Antigen/immunology , Receptors, IgE/immunology , T-Cell Antigen Receptor Specificity/immunology , Antibody Affinity/immunology , Antibody-Dependent Cell Cytotoxicity/immunology , Asthma/immunology , Asthma/therapy , Cell Line , Cell Line, Tumor , Humans , Immunoglobulin E/genetics , Immunoglobulin E/metabolism , Immunotherapy, Adoptive/methods , Jurkat Cells , Mutation , Receptors, Chimeric Antigen/genetics , Receptors, Chimeric Antigen/metabolism , Receptors, IgE/genetics , Receptors, IgE/metabolism , T-Cell Antigen Receptor Specificity/genetics , T-Lymphocytes/immunology , T-Lymphocytes/metabolism
7.
Int J Nanomedicine ; 10: 6931-41, 2015.
Article in English | MEDLINE | ID: mdl-26609231

ABSTRACT

Nanoshell-mediated photothermal therapy (PTT) is currently being investigated as a standalone therapy for the treatment of cancer. The cellular effects of PTT include loss of membrane integrity, so we hypothesized that nanoshell-mediated PTT could potentiate the cytotoxicity of chemotherapy by improving drug accumulation in cancer cells. In this work, we validated our hypothesis using doxorubicin as a model drug and SUM149 inflammatory breast cancer cells as a model cancer subtype. In initial studies, SUM149 cells were exposed to nano-shells and near-infrared light and then stained with ethidium homodimer-1, which is excluded from cells with an intact plasma membrane. The results confirmed that nanoshell-mediated PTT could increase membrane permeability in SUM149 cells. In complementary experiments, SUM149 cells treated with nanoshells, near-infrared light, or a combination of the two to yield low-dose PTT were exposed to fluorescent rhodamine 123. Analyzing rhodamine 123 fluorescence in cells via flow cytometry confirmed that increased membrane permeability caused by PTT could enhance drug accumulation in cells. This was validated using fluorescence microscopy to assess intracellular distribution of doxorubicin. In succeeding experiments, SUM149 cells were exposed to subtherapeutic levels of doxorubicin, low-dose PTT, or a combination of the two treatments to determine whether the additional drug uptake induced by PTT is sufficient to enhance cell death. Analysis revealed minimal loss of viability relative to controls in cells exposed to subtherapeutic levels of doxorubicin, 15% loss of viability in cells exposed to low-dose PTT, and 35% loss of viability in cells exposed to combination therapy. These data indicate that nanoshell-mediated PTT is a viable strategy to potentiate the effects of chemotherapy and warrant further investigation of this approach using other drugs and cancer subtypes.


Subject(s)
Antineoplastic Agents/therapeutic use , Inflammatory Breast Neoplasms/drug therapy , Nanoshells/chemistry , Phototherapy , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Cell Membrane Permeability/drug effects , Cell Survival/drug effects , Combined Modality Therapy , Doxorubicin/pharmacology , Doxorubicin/therapeutic use , Female , Humans , Hyperthermia, Induced , Infrared Rays , Nanoshells/ultrastructure , Rhodamines/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...